Obesity evidence: the SCALE program
At the higher 3.0 mg dose, liraglutide became Saxenda, approved for chronic weight management under its own FDA…
A second approval, at a higher dose
At the higher 3.0 mg dose, liraglutide became Saxenda, approved for chronic weight management under its own FDA application. The evidence came from the SCALE program: large randomized trials in people with obesity, with and without diabetes, plus studies of prevention, maintenance, and sleep apnea.
This unit walks the SCALE results honestly. The weight loss is real and clinically useful. The Saxenda label prints it as -7.4%, -5.4% and -4.9% across three adult trials, three different populations the label says must not be averaged into one number, and all of them noticeably smaller than semaglutide in STEP 8, the head-to-head at weight-management doses. Holding both facts, genuine benefit and modest magnitude, is the whole skill here.